Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
HERMES trial: what clinicians have said so far
Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer
- NCT04595019 ↗
- Recruiting
- Institute of Cancer Research, United Kingdom
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on HERMES yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HERMES so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- The HERMES Trial Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer. A Phase II Randomised Trial of Ultrahypofractionated Stereotactic Body Radiotherapy in Men With Localised Prostate Cancer
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- Prostate Cancer
- Interventions
- SBRT
- Arms
- 5 fraction · Active comparator
- 2 fraction · Experimental
- Enrollment
- 46 (estimated)
- Primary outcomes
- Genitourinary (GU) toxicity
- Sponsor
- Institute of Cancer Research, United Kingdom
- Start
- Jul 29, 2021
- Primary completion
- Apr 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04595019 · updated Jun 13, 2022